Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00773513




Registration number
NCT00773513
Ethics application status
Date submitted
15/10/2008
Date registered
16/10/2008
Date last updated
20/08/2019

Titles & IDs
Public title
A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)
Scientific title
A Randomized, Controlled, Open-Label, Multi-Centre, Parallel-Group Study To Assess All-Cause Mortality And Cardiovascular Morbidity In Patients With Chronic Kidney Disease On Dialysis And Those Not On Renal Replacement Therapy Under Treatment With MIRCERA® Or Reference ESAs.
Secondary ID [1] 0 0
2007-005129-31
Secondary ID [2] 0 0
BH21260
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Renal Anemia 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Kidney disease
Renal and Urogenital 0 0 0 0
Other renal and urogenital disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Darbepoetin Alfa
Treatment: Drugs - Epoetin Alfa
Treatment: Drugs - Epoetin Beta
Treatment: Drugs - methoxy polyethylene glycol-epoetin beta

Active comparator: Erythropoiesis Stimulating Agents - Participants will receive reference ESA according to approved label. The approved reference ESA compounds in the study will be darbepoetin alfa, epoetin alfa and epoetin beta.

Experimental: Methoxy Polyethylene Glycol-Epoetin Beta - Participants not currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta iv or sc once every 2 weeks for correction of renal anemia (target Hb 10-12 g/dL). Once corrected and in participants currently being treated with an ESA, methoxy polyethylene glycol-epoetin beta will be administered once monthly.


Treatment: Drugs: Darbepoetin Alfa
Darbepoetin alfa will be administered as per approved label.

Treatment: Drugs: Epoetin Alfa
Epoetin alfa will be administered as per approved label.

Treatment: Drugs: Epoetin Beta
Epoetin beta will be administered as per approved label.

Treatment: Drugs: methoxy polyethylene glycol-epoetin beta
Participants who are currently not being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta administered at a starting dose of 0.6 mcg/kg body weight once every 2 weeks. Participants who are currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta at a dose of 120, 200 or 360 mcg once monthly (based on ESA dose administered in Week -1)
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to Composite of All-Cause Mortality and Non-Fatal Cardiovascular Events (Myocardial Infarction, Stroke) Defined as Time Between First Dose of Study Medication and Date of Death or Non-Fatal Cardiovascular Events, Whichever Occurred First
Timepoint [1] 0 0
Baseline up to approximately 8.5 years
Secondary outcome [1] 0 0
Time to All-Cause Mortality
Timepoint [1] 0 0
Baseline up to approximately 8.5 years
Secondary outcome [2] 0 0
Time to Non-Fatal and Fatal Myocardial Infarction
Timepoint [2] 0 0
Baseline up to approximately 8.5 years
Secondary outcome [3] 0 0
Time to Non-Fatal and Fatal Stroke
Timepoint [3] 0 0
Baseline up to approximately 8.5 years
Secondary outcome [4] 0 0
Time to Non-Fatal Cardiovascular Events (Myocardial Infarction or Stroke, Whichever Occurred First)
Timepoint [4] 0 0
Baseline up to approximately 8.5 years
Secondary outcome [5] 0 0
Percentage of Participants With Anti-Erythropoietin Antibody-Mediated Pure Red Cell Aplasia (PRCA)
Timepoint [5] 0 0
Baseline up to approximately 8.5 years
Secondary outcome [6] 0 0
Percentage of Participants With Gastrointestinal Bleeding
Timepoint [6] 0 0
Baseline up to approximately 8.5 years
Secondary outcome [7] 0 0
Percentage of Participants With Thromboembolic Events
Timepoint [7] 0 0
Baseline up to approximately 8.5 years

Eligibility
Key inclusion criteria
* Male or female participants with symptomatic anemia associated with CKD
* Participants with renal anemia who are not treated with an ESA:
* Anemia was defined as hemoglobin (Hb) concentration less than (<) 11.0 grams per deciliter (g/dL) (mean of 2 screening values with at least one day and a maximum of 2 weeks between measurements) with clinical indication for ESA treatment
* Participants with renal anemia who are on maintenance ESA therapy:
* If on dialysis: regular long-term hemodialysis or peritoneal dialysis therapy with the same mode of dialysis for at least 3 months before screening
* Hb concentration between 10 and 12 g/dL (mean of 2 screening values with at least one day and a maximum of 2 weeks between measurements)
* Participants with adequate iron status defined as: serum ferritin above or equal to 100 micrograms per liter or transferrin saturation above or equal to 20 percent
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Contraindications to ESA treatment: uncontrolled hypertension, hypersensitivity to the active substance or any of the excipients, any other contraindication to ESA therapy
* Conditions known to cause inadequate response to ESA treatment or anemia other than symptomatic anemia associated with CKD:
* History of hemoglobinopathy
* Anemia due to hemolysis
* Pure red cell aplasia
* High likelihood of early withdrawal (for example, within 1 year) or interruption of the study
* Pregnancy or breast-feeding
* Women of childbearing potential without effective contraception
* Administration of another investigational drug within 1 month before screening or planned during the study period

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
12/12/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
27/07/2017
Sample size
Target
Accrual to date
Final
2825
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC,WA
Recruitment hospital [1] 0 0
Gosford Hospital; Renal - Gosford
Recruitment hospital [2] 0 0
Renal Research Dr Simon Roger - Gosford
Recruitment hospital [3] 0 0
Cairns Hospital; Renal Services - Cairns
Recruitment hospital [4] 0 0
Gold Coast Hospital Department of Pharmacology & Therapeutics - Southport
Recruitment hospital [5] 0 0
ROYAL ADELAIDE HOSPITAL; Renal Clinical Trials, CNARTS - Adelaide
Recruitment hospital [6] 0 0
Launceston General Hospital; Diabetes and Renal Research Unit - Launceston
Recruitment hospital [7] 0 0
Monash Medical Centre; Renal Transplant Unit - Clayton
Recruitment hospital [8] 0 0
Royal Perth Hospital; Nephrology - Perth
Recruitment postcode(s) [1] 0 0
2250 - Gosford
Recruitment postcode(s) [2] 0 0
4870 - Cairns
Recruitment postcode(s) [3] 0 0
4215 - Southport
Recruitment postcode(s) [4] 0 0
5000 - Adelaide
Recruitment postcode(s) [5] 0 0
7250 - Launceston
Recruitment postcode(s) [6] 0 0
3186 - Clayton
Recruitment postcode(s) [7] 0 0
6847 - Perth
Recruitment outside Australia
Country [1] 0 0
Argentina
State/province [1] 0 0
Buenos Aires
Country [2] 0 0
Argentina
State/province [2] 0 0
Caba
Country [3] 0 0
Belgium
State/province [3] 0 0
Brussel
Country [4] 0 0
Belgium
State/province [4] 0 0
Gent
Country [5] 0 0
Belgium
State/province [5] 0 0
Hasselt
Country [6] 0 0
Belgium
State/province [6] 0 0
Leuven
Country [7] 0 0
Belgium
State/province [7] 0 0
Roeselare
Country [8] 0 0
Brazil
State/province [8] 0 0
MG
Country [9] 0 0
Brazil
State/province [9] 0 0
PR
Country [10] 0 0
Brazil
State/province [10] 0 0
RJ
Country [11] 0 0
Brazil
State/province [11] 0 0
RS
Country [12] 0 0
Brazil
State/province [12] 0 0
SP
Country [13] 0 0
Croatia
State/province [13] 0 0
Karlovac
Country [14] 0 0
Croatia
State/province [14] 0 0
Osijek
Country [15] 0 0
Croatia
State/province [15] 0 0
Rijeka
Country [16] 0 0
Croatia
State/province [16] 0 0
Slavonski Brod
Country [17] 0 0
Croatia
State/province [17] 0 0
Split
Country [18] 0 0
Croatia
State/province [18] 0 0
Zadar
Country [19] 0 0
Croatia
State/province [19] 0 0
Zagreb
Country [20] 0 0
Czechia
State/province [20] 0 0
Hradec Kralove
Country [21] 0 0
Czechia
State/province [21] 0 0
Ostrava
Country [22] 0 0
Czechia
State/province [22] 0 0
Praha 6
Country [23] 0 0
Czechia
State/province [23] 0 0
Praha
Country [24] 0 0
France
State/province [24] 0 0
Annonay
Country [25] 0 0
France
State/province [25] 0 0
Bordeaux
Country [26] 0 0
France
State/province [26] 0 0
Boulogne
Country [27] 0 0
France
State/province [27] 0 0
Brest
Country [28] 0 0
France
State/province [28] 0 0
Colmar
Country [29] 0 0
France
State/province [29] 0 0
La Garenne-Colombes
Country [30] 0 0
France
State/province [30] 0 0
Limoges
Country [31] 0 0
France
State/province [31] 0 0
Lyon
Country [32] 0 0
France
State/province [32] 0 0
Macon
Country [33] 0 0
France
State/province [33] 0 0
Nantes
Country [34] 0 0
France
State/province [34] 0 0
Nimes
Country [35] 0 0
France
State/province [35] 0 0
Paris
Country [36] 0 0
France
State/province [36] 0 0
Saint Herblain
Country [37] 0 0
France
State/province [37] 0 0
Salouel
Country [38] 0 0
France
State/province [38] 0 0
Strasbourg
Country [39] 0 0
France
State/province [39] 0 0
Toulouse
Country [40] 0 0
France
State/province [40] 0 0
Valenciennes
Country [41] 0 0
Germany
State/province [41] 0 0
Alsfeld
Country [42] 0 0
Germany
State/province [42] 0 0
Bad Hersfeld
Country [43] 0 0
Germany
State/province [43] 0 0
Bonn
Country [44] 0 0
Germany
State/province [44] 0 0
Demmin
Country [45] 0 0
Germany
State/province [45] 0 0
Düsseldorf
Country [46] 0 0
Germany
State/province [46] 0 0
Erlangen
Country [47] 0 0
Germany
State/province [47] 0 0
Gießen
Country [48] 0 0
Germany
State/province [48] 0 0
Hamburg
Country [49] 0 0
Germany
State/province [49] 0 0
Hann. Münden
Country [50] 0 0
Germany
State/province [50] 0 0
Heidelberg
Country [51] 0 0
Germany
State/province [51] 0 0
Homburg/Saar
Country [52] 0 0
Germany
State/province [52] 0 0
Kiel
Country [53] 0 0
Germany
State/province [53] 0 0
München
Country [54] 0 0
Germany
State/province [54] 0 0
Oberschleissheim
Country [55] 0 0
Germany
State/province [55] 0 0
Rostock
Country [56] 0 0
Germany
State/province [56] 0 0
Schwandorf
Country [57] 0 0
Germany
State/province [57] 0 0
Stuttgart
Country [58] 0 0
Greece
State/province [58] 0 0
Alexandroupolis
Country [59] 0 0
Greece
State/province [59] 0 0
Athens
Country [60] 0 0
Greece
State/province [60] 0 0
Ioannina
Country [61] 0 0
Greece
State/province [61] 0 0
Larissa
Country [62] 0 0
Greece
State/province [62] 0 0
Thessaloniki
Country [63] 0 0
Israel
State/province [63] 0 0
Petach Tikva
Country [64] 0 0
Israel
State/province [64] 0 0
Petah Tikva
Country [65] 0 0
Israel
State/province [65] 0 0
Ramat-Gan
Country [66] 0 0
Israel
State/province [66] 0 0
Tel Aviv
Country [67] 0 0
Israel
State/province [67] 0 0
Zrifin
Country [68] 0 0
Italy
State/province [68] 0 0
Emilia-Romagna
Country [69] 0 0
Italy
State/province [69] 0 0
Lazio
Country [70] 0 0
Italy
State/province [70] 0 0
Liguria
Country [71] 0 0
Italy
State/province [71] 0 0
Lombardia
Country [72] 0 0
Italy
State/province [72] 0 0
Marche
Country [73] 0 0
Italy
State/province [73] 0 0
Sicilia
Country [74] 0 0
Italy
State/province [74] 0 0
Toscana
Country [75] 0 0
Italy
State/province [75] 0 0
Veneto
Country [76] 0 0
Korea, Republic of
State/province [76] 0 0
Seoul
Country [77] 0 0
Lithuania
State/province [77] 0 0
Kaunas
Country [78] 0 0
Lithuania
State/province [78] 0 0
Vilnius
Country [79] 0 0
Malaysia
State/province [79] 0 0
FED. Territory OF Kuala Lumpur
Country [80] 0 0
Malaysia
State/province [80] 0 0
Kuala Lumpur
Country [81] 0 0
Malaysia
State/province [81] 0 0
Selangor
Country [82] 0 0
Mexico
State/province [82] 0 0
Morelos
Country [83] 0 0
Panama
State/province [83] 0 0
Panama
Country [84] 0 0
Philippines
State/province [84] 0 0
CEBU City
Country [85] 0 0
Philippines
State/province [85] 0 0
Quezon City
Country [86] 0 0
Poland
State/province [86] 0 0
Bydgoszcz
Country [87] 0 0
Poland
State/province [87] 0 0
Ciechanow
Country [88] 0 0
Poland
State/province [88] 0 0
Dabrowa Tarnowska
Country [89] 0 0
Poland
State/province [89] 0 0
Gorlice
Country [90] 0 0
Poland
State/province [90] 0 0
Jaslo
Country [91] 0 0
Poland
State/province [91] 0 0
Limanowa
Country [92] 0 0
Poland
State/province [92] 0 0
Pabianice
Country [93] 0 0
Poland
State/province [93] 0 0
Poznan
Country [94] 0 0
Poland
State/province [94] 0 0
Rzeszow
Country [95] 0 0
Poland
State/province [95] 0 0
Sandomierz
Country [96] 0 0
Poland
State/province [96] 0 0
Skierniewice
Country [97] 0 0
Poland
State/province [97] 0 0
Stalowa Wola
Country [98] 0 0
Poland
State/province [98] 0 0
Walbrzych
Country [99] 0 0
Poland
State/province [99] 0 0
Zamosc
Country [100] 0 0
Russian Federation
State/province [100] 0 0
Leningrad
Country [101] 0 0
Russian Federation
State/province [101] 0 0
Saint-Petersburg
Country [102] 0 0
Russian Federation
State/province [102] 0 0
St.Petersburg
Country [103] 0 0
Serbia
State/province [103] 0 0
Belgrade
Country [104] 0 0
Serbia
State/province [104] 0 0
NIS
Country [105] 0 0
Serbia
State/province [105] 0 0
Novi Sad
Country [106] 0 0
Singapore
State/province [106] 0 0
Singapore
Country [107] 0 0
Spain
State/province [107] 0 0
Alava
Country [108] 0 0
Spain
State/province [108] 0 0
Almeria
Country [109] 0 0
Spain
State/province [109] 0 0
Madrid
Country [110] 0 0
Spain
State/province [110] 0 0
Navarra
Country [111] 0 0
Spain
State/province [111] 0 0
Vizcaya
Country [112] 0 0
Spain
State/province [112] 0 0
Barcelona
Country [113] 0 0
Spain
State/province [113] 0 0
Granada
Country [114] 0 0
Spain
State/province [114] 0 0
Jaen
Country [115] 0 0
Sweden
State/province [115] 0 0
Danderyd
Country [116] 0 0
Sweden
State/province [116] 0 0
Eskilstuna
Country [117] 0 0
Sweden
State/province [117] 0 0
Uppsala
Country [118] 0 0
Taiwan
State/province [118] 0 0
Kaohsiung
Country [119] 0 0
Taiwan
State/province [119] 0 0
Taipei
Country [120] 0 0
Thailand
State/province [120] 0 0
Bangkok
Country [121] 0 0
Thailand
State/province [121] 0 0
Chiang Mai
Country [122] 0 0
Thailand
State/province [122] 0 0
Phitsanulok
Country [123] 0 0
Turkey
State/province [123] 0 0
Adana
Country [124] 0 0
Turkey
State/province [124] 0 0
Ankara
Country [125] 0 0
Turkey
State/province [125] 0 0
Malatya
Country [126] 0 0
United Kingdom
State/province [126] 0 0
Belfast
Country [127] 0 0
United Kingdom
State/province [127] 0 0
Bradford
Country [128] 0 0
United Kingdom
State/province [128] 0 0
Cardiff
Country [129] 0 0
United Kingdom
State/province [129] 0 0
Carshalton
Country [130] 0 0
United Kingdom
State/province [130] 0 0
Coventry
Country [131] 0 0
United Kingdom
State/province [131] 0 0
Dorchester
Country [132] 0 0
United Kingdom
State/province [132] 0 0
Exeter
Country [133] 0 0
United Kingdom
State/province [133] 0 0
Hull
Country [134] 0 0
United Kingdom
State/province [134] 0 0
Ipswich
Country [135] 0 0
United Kingdom
State/province [135] 0 0
Leeds
Country [136] 0 0
United Kingdom
State/province [136] 0 0
Leicester
Country [137] 0 0
United Kingdom
State/province [137] 0 0
London
Country [138] 0 0
United Kingdom
State/province [138] 0 0
Middlesborough
Country [139] 0 0
United Kingdom
State/province [139] 0 0
Newcastle Upon Tyne
Country [140] 0 0
United Kingdom
State/province [140] 0 0
Oxford
Country [141] 0 0
United Kingdom
State/province [141] 0 0
Plymouth
Country [142] 0 0
United Kingdom
State/province [142] 0 0
Preston
Country [143] 0 0
United Kingdom
State/province [143] 0 0
Salford
Country [144] 0 0
United Kingdom
State/province [144] 0 0
Shrewsbury
Country [145] 0 0
United Kingdom
State/province [145] 0 0
Swansea
Country [146] 0 0
United Kingdom
State/province [146] 0 0
Truro
Country [147] 0 0
United Kingdom
State/province [147] 0 0
West Sussex

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This 2 arm safety study will compare the outcome with respect to a composite endpoint of all-cause mortality and non-fatal cardiovascular events (myocardial infarction, stroke) in CKD participants either on dialysis or not receiving renal replacement therapy under treatment with methoxy polyethylene glycol-epoetin beta or reference ESAs. Participants will be randomized to receive intravenous (iv) or subcutaneous (sc) methoxy polyethylene glycol-epoetin beta at the following doses: for participants not already receiving ESA treatment, methoxy polyethylene glycol-epoetin beta will be administered at a starting dose of 0.6 micrograms per kilograms every 2 weeks (mcg/kg/2wks) iv or sc; for participants receiving maintenance ESA treatment, iv or sc methoxy polyethylene glycol-epoetin beta will be administered at an initial monthly dose of 120, 200 or 360 micrograms (mcg) depending on the weekly dose of ESA received prior to first methoxy polyethylene glycol-epoetin beta administration. Participants randomized to reference ESA treatment will receive iv or sc ESAs in accordance with their prescribed dosing information.
Trial website
https://clinicaltrials.gov/study/NCT00773513
Trial related presentations / publications
Locatelli F, Hannedouche T, Fishbane S, Morgan Z, Oguey D, White WB. Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial. Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1701-1710. doi: 10.2215/CJN.01380219. Epub 2019 Aug 16.
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00773513